FEATURES
Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.
 

 
By Dr. Dragan Cicic, Actinium Pharmaceuticals Inc.
Patients with blood cancers often face poor long-term survival outcomes, but a new treatment approach could offer more effective targeting of cancer cells as well as lower toxicity.
 
By Kelsey Kaustinen, DDNews Senior Editor
If all milestones are met, the agreement could be worth up to $817 million
 
By Kelsey Kaustinen, DDNews Senior Editor
The effectiveness of anthracyclines, a standard of cancer care, is marred by the associated heart damage they cause; a recent study, however, reports that wrapping the drugs in a fatty cover can minimize cardiotoxicity.
 
By Lloyd Dunlap, DDNews Managing Editor
Immunomedics Inc. has received notice from the U.S. Food and Drug Administration designating as a Fast Track development program the investigation of sacituzumab govitecan, the company's lead antibody-drug conjugate, for the treatment of patients with triple-negative breast cancer
 
By Kelsey Kaustinen, DDNews Senior Editor
When the STP axis is expressed, causing low REST protein levels, clinical outcomes in the lab are poor, while inhibition of the axis was found to increase REST levels, which impaired tumor formation and progression.
 
 
 

 
 
Agios, iNovacia announce new collaboration
March 2012
SHARING OPTIONS:

STOCKHOLM, Sweden—iNovacia AB has announced a high-throughput screening collaboration with Cambridge, Mass.-based Agios Pharmaceuticals, a company focusing on cancer metabolism. Per the terms of the agreement, iNovacia will provide small-molecule lead generation services for the collaboration in addition to identifying modulators of pharmaceutical targets of interest to Agios through use of iNovacia's proprietary screening library. Financial details for the collaboration were not disclosed.
 
"We have had successful screening projects with Agios in the past and we are now proud to be able to extend this relationship," Dr. Thomas Olin, CEO of iNovacia, said in a press release. "We are pleased that Agios and other U.S. and European companies continue to appreciate the value of our premium screening operations and proprietary screening library as a means to generate high-quality chemistry starting points."

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2015 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.